

**Contact**

Merck KGaA, Darmstadt, Germany  
Investor Relations  
Frankfurter Strasse 250  
64293 Darmstadt  
Germany  
Phone: +49 6151 72 3321  
e-mail: investor.relations@merckgroup.com  
www.merckgroup.com

WKN: 659990  
ISIN: DE0006599905  
Ticker Symbol: MRK

# Financial Statements Q1 2018 – Q4 2018

**Content**

---

**1 Income statements**

- 1.1 Group, quarterly
- 1.2 Healthcare, quarterly
- 1.3 Life Science, quarterly
- 1.4 Performance Materials, quarterly
- 1.5 Corporate/Others, quarterly

**2 Cash flow statement****3 Balance sheet**

**EBITDA pre Merck KGaA, Darmstadt, Germany**

€ million	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
Healthcare	381,4	378,5	759,9	381,5	1 141,4	414,3	795,8	1 555,7
<i>in % of net sales</i>	26,6%	23,9%	25,2%	23,9%	24,7%	25,4%	24,7%	24,9%
Life Science	454,6	451,8	906,4	460,3	1 366,7	473,6	933,9	1 840,3
<i>in % of net sales</i>	30,6%	29,3%	29,9%	30,1%	30,0%	29,1%	29,6%	29,8%
Performance Materials	195,7	195,8	391,5	203,2	594,7	190,9	394,0	785,5
<i>in % of net sales</i>	34,7%	33,4%	34,0%	32,5%	33,5%	30,3%	31,4%	32,7%
Corporate/Others	-64,6	-106,0	-170,6	-81,7	-252,4	-129,1	-210,8	-381,5
<b>Group</b>	<b>967,1</b>	<b>920,0</b>	<b>1 887,1</b>	<b>963,3</b>	<b>2 850,4</b>	<b>949,6</b>	<b>1 912,9</b>	<b>3 800,0</b>
<i>in % of net sales</i>	27,7%	24,8%	26,2%	25,7%	26,0%	24,4%	25,0%	25,6%

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**

Group	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
€ million								
<b>Net sales</b>	<b>3 485,7</b>	<b>3 713,6</b>	<b>7 199,3</b>	<b>3 749,4</b>	<b>10 948,7</b>	<b>3 887,6</b>	<b>7 637,0</b>	<b>14 836,3</b>
Cost of sales	-1 260,0	-1 321,4	-2 581,3	-1 344,1	-3 925,5	-1 456,3	-2 800,5	-5 381,8
thereof amortization of intangible assets	-43,1	-43,9	-87,1	-43,9	-130,9	-44,6	-88,4	-175,5
Gross profit	2 225,8	2 392,2	4 617,9	2 405,3	7 023,2	2 431,3	4 836,5	9 454,5
<i>in % of net sales</i>	63,9%	64,4%	64,1%	64,2%	64,1%	62,5%	63,3%	63,7%
SG&A	-1 215,9	-1 461,5	-2 677,4	-1 372,0	-4 049,4	-1 451,3	-2 823,3	-5 500,7
<i>in % of net sales</i>	34,9%	39,4%	37,2%	36,6%	37,0%	37,3%	37,0%	37,1%
Marketing and selling expenses	-1 020,7	-1 108,8	-2 129,5	-1 078,8	-3 208,2	-1 188,2	-2 267,0	-4 396,4
thereof amortization of intangible assets (M&S)	-245,2	-243,8	-489,0	-241,5	-730,4	-244,2	-485,7	-974,7
Administration expenses	-257,3	-274,8	-532,2	-283,1	-815,3	-368,1	-651,2	-1 183,4
Impairment losses and reversals (IFRS 9)	-2,4	-5,7	-8,1	32,3	24,2	3,2	35,5	27,4
Other operating expenses/income	64,5	-72,2	-7,6	-42,5	-50,1	101,8	59,4	51,7
Impairments**	0,0	-17,4	-17,4	-4,5	-21,9	-33,1	-37,6	-55,0
Research and development	-507,6	-538,3	-1 046,0	-542,2	-1 588,2	-639,0	-1 181,3	-2 227,3
<i>in % of net sales</i>	14,6%	14,5%	14,5%	14,5%	14,5%	16,4%	15,5%	15,0%
thereof amortization of intangible assets (R&D)	-1,1	-1,3	-2,4	-1,2	-3,6	-21,1	-22,3	-24,7
<b>EBIT</b>	<b>502,2</b>	<b>392,4</b>	<b>894,6</b>	<b>491,0</b>	<b>1 385,6</b>	<b>340,9</b>	<b>832,0</b>	<b>1 726,5</b>
<i>in % of net sales</i>	14,4%	10,6%	12,4%	13,1%	12,7%	8,8%	10,9%	11,6%
Depreciation and amortization	422,0	447,8	869,8	427,6	1 297,4	503,6	931,2	1 801,0
<b>EBITDA</b>	<b>924,2</b>	<b>840,1</b>	<b>1 764,4</b>	<b>918,7</b>	<b>2 683,0</b>	<b>844,5</b>	<b>1 763,1</b>	<b>3 527,5</b>
<i>in % of net sales</i>	26,5%	22,6%	24,5%	24,5%	24,5%	21,7%	23,1%	23,8%
<b>EBITDA pre</b>	<b>967,1</b>	<b>920,0</b>	<b>1 887,1</b>	<b>963,3</b>	<b>2 850,4</b>	<b>949,6</b>	<b>1 912,9</b>	<b>3 800,0</b>
<i>in % of net sales</i>	27,7%	24,8%	26,2%	25,7%	26,0%	24,4%	25,0%	25,6%
Financial result	-61,2	-64,6	-125,8	-55,9	-181,7	-84,2	-140,1	-265,9
Profit before income tax from continuing operations	441,0	327,8	768,8	435,1	1 203,9	256,7	691,8	1 460,6
Income tax	-108,1	-83,7	-191,8	-111,6	-303,4	-64,1	-175,7	-367,5
<i>Income tax rate</i>	24,5%	25,5%	24,9%	25,7%	25,2%	25,0%	25,4%	25,2%
Profit after tax from continuing operations	332,9	244,1	577,0	323,5	900,5	192,6	516,1	1 093,1
Profit after tax from discontinued operations	9,0	6,5	15,6	21,8	37,4	2 265,5	2 287,3	2 302,9
Profit after tax	342,0	250,6	592,6	345,3	937,9	2 458,1	2 803,4	3 396,0
<b>of which: attributable to Merck KGaA shareholders (net)</b>	<b>341,0</b>	<b>246,8</b>	<b>587,8</b>	<b>340,2</b>	<b>928,0</b>	<b>2 445,7</b>	<b>2 785,9</b>	<b>3 373,7</b>
<b>of which: attributable to non-controlling interests</b>	<b>1,0</b>	<b>3,9</b>	<b>4,8</b>	<b>5,1</b>	<b>9,9</b>	<b>12,4</b>	<b>17,5</b>	<b>22,3</b>
<b>EPS in €</b>	<b>0,78</b>	<b>0,57</b>	<b>1,35</b>	<b>0,78</b>	<b>2,13</b>	<b>5,63</b>	<b>6,41</b>	<b>7,76</b>
thereof from continuing operations	0,76	0,56	1,32	0,74	2,06	0,45	1,19	2,51
thereof from discontinued operations	0,02	0,01	0,03	0,04	0,07	5,18	5,22	5,25

<b>EPS pre in €*</b>	<b>1,33</b>	<b>1,23</b>	<b>2,56</b>	<b>1,32</b>	<b>3,89</b>	<b>1,22</b>	<b>2,54</b>	<b>5,10</b>
<b>Number of theoretical shares in million</b>	434,8	434,8	434,8	434,8	434,8	434,8	434,8	434,8
<b>Reconciliation to EBITDA pre</b>								
EBITDA	924,2	840,1	1 764,4	918,7	2 683,0	844,5	1 763,1	3 527,5
<b>Adjustments</b>								
thereof: Cost of Sales	3,0	3,3	6,4	-4,6	1,8	43,0	38,4	44,8
thereof: Marketing and selling expenses	0,4	1,9	2,3	1,4	3,7	9,2	10,5	12,9
thereof: Administration expenses	36,3	38,7	75,0	43,5	118,6	71,4	114,9	189,9
thereof: Other operating expenses/income	3,0	35,9	38,9	4,2	43,1	-20,5	-16,3	22,6
thereof: Research and development	0,1	0,1	0,1	0,1	0,2	2,2	2,2	2,4
<b>Total</b>	<b>42,9</b>	<b>79,9</b>	<b>122,8</b>	<b>44,6</b>	<b>167,3</b>	<b>105,2</b>	<b>149,7</b>	<b>272,5</b>
<b>EBITDA pre</b>	<b>967,1</b>	<b>920,0</b>	<b>1 887,1</b>	<b>963,3</b>	<b>2 850,4</b>	<b>949,6</b>	<b>1 912,9</b>	<b>3 800,0</b>

Sum of items may not foot due to rounding.

\* for continuing operations

\*\* only reflects impairments which classified as adjustments

**Reconciliation to EBITDA, EBITDA pre and EPS pre**
**Group**

€ million

	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>a) Reconciliation to EBITDA and EBITDA pre</b>								
<b>EBITDA</b>								
EBIT	502,2	392,4	894,6	491,0	1 385,6	340,9	832,0	1 726,5
Depreciation and amortization	422,0	447,8	869,8	427,6	1 297,4	503,6	931,2	1 801,0
Regular depreciation and amortization*	132,6	141,5	274,1	136,6	410,7	160,7	297,3	571,3
Amortization of purchased intangible assets	289,4	288,9	578,3	286,5	864,8	309,8	596,3	1 174,6
Impairments**	0,0	17,4	17,4	4,5	21,9	33,1	37,6	55,0
<b>Total</b>	<b>924,2</b>	<b>840,1</b>	<b>1 764,4</b>	<b>918,7</b>	<b>2 683,0</b>	<b>844,5</b>	<b>1 763,1</b>	<b>3 527,5</b>
<b>Adjustments</b>								
Acquisition costs	0,6	0,3	0,8	0,9	1,7	0,0	1,0	1,8
Restructuring costs	5,6	10,5	16,1	9,3	25,4	20,7	30,0	46,1
Integration costs/IT costs	20,9	21,5	42,3	22,7	65,0	77,0	99,7	142,0
Gain (-)/ losses (+) on the divestment of businesses	1,9	37,0	38,9	3,7	42,6	-18,0	-14,3	24,6
Other one-time costs	14,0	10,6	24,6	8,0	32,6	25,4	33,4	58,0
<b>Total</b>	<b>42,9</b>	<b>79,9</b>	<b>122,8</b>	<b>44,6</b>	<b>167,3</b>	<b>105,2</b>	<b>149,7</b>	<b>272,5</b>
<b>EBITDA pre</b>	<b>967,1</b>	<b>920,0</b>	<b>1 887,1</b>	<b>963,3</b>	<b>2 850,4</b>	<b>949,6</b>	<b>1 912,9</b>	<b>3 800,0</b>

**b) Reconciliation to EPS pre**
**1) Reconciliation starting from EBITDA pre**

EBITDA pre	967,1	920,0	1 887,1	963,3	2 850,4	949,6	1 912,9	3 800,0
Regular depreciation and amortization*	-132,6	-141,5	-274,1	-136,6	-410,7	-160,7	-297,3	-571,3
Financial result	-61,2	-64,6	-125,8	-55,9	-181,7	-84,2	-140,1	-265,9
Profit before income tax pre	773,3	714,0	1 487,2	770,7	2 258,0	704,8	1 475,5	2 962,8
Income tax pre	-193,3	-178,5	-371,8	-192,7	-564,5	-176,2	-368,9	-740,7
<i>underlying tax rate</i>	25,0%	25,0%	25,0%	25,0%	25,0%	25,0%	25,0%	25,0%
Non-controlling interest	-0,8	-0,5	-1,3	-2,4	-3,7	0,6	-3,1	-3,1
Net income pre	579,2	535,0	1 114,2	575,6	1 689,8	529,2	1 103,6	2 219,1
<b>EPS pre in €***</b>	<b>1,33</b>	<b>1,23</b>	<b>2,56</b>	<b>1,32</b>	<b>3,89</b>	<b>1,22</b>	<b>2,54</b>	<b>5,10</b>

**2) Reconciliation starting from Profit before tax**

Profit before income tax	441,0	327,8	768,8	435,1	1 203,9	256,7	691,8	1 460,6
Amortization of purchased intangible assets	289,4	288,9	578,3	286,5	864,8	309,8	596,3	1 174,6
Impairments**	0,0	17,4	17,4	4,5	21,9	33,1	37,6	55,0
<b>Adjustments</b>								
Acquisition costs	0,6	0,3	0,8	0,9	1,7	0,0	1,0	1,8
Restructuring costs	5,6	10,5	16,1	9,3	25,4	20,7	30,0	46,1
Integration costs/IT costs	20,9	21,5	42,3	22,7	65,0	77,0	99,7	142,0

Gain (-)/ losses (+) on the divestment of businesses	1,9	37,0	38,9	3,7	42,6	-18,0	-14,3	24,6
Other one-time costs	14,0	10,6	24,6	8,0	32,6	25,4	33,4	58,0
Total adjustments	42,9	79,9	122,8	44,6	167,3	105,2	149,7	272,5
Profit before income tax pre	773,3	714,0	1 487,2	770,7	2 257,9	704,8	1 475,4	2 962,7
Income tax pre	-193,3	-178,5	-371,8	-192,7	-564,5	-176,2	-368,9	-740,7
<i>underlying tax rate</i>	<i>25,0%</i>	<i>25,0%</i>	<i>25,0%</i>	<i>25,0%</i>	<i>25,0%</i>	<i>25,0%</i>	<i>25,0%</i>	<i>25,0%</i>
<b>Total costs excluded from Net income</b>	<b>238,2</b>	<b>288,2</b>	<b>526,4</b>	<b>235,4</b>	<b>761,8</b>	<b>-1 916,6</b>	<b>-1 682,4</b>	<b>-1 154,7</b>
Total costs excluded from EPS in €	0,55	0,66	1,21	0,54	1,75	-4,41	-3,87	-2,66
Non-controlling interest	-0,8	-0,5	-1,3	-2,4	-3,7	0,6	-3,1	-3,1
Net income pre	579,2	535,0	1 114,2	575,6	1 689,8	529,2	1 103,5	2 218,9
<b>EPS pre in €***</b>	<b>1,33</b>	<b>1,23</b>	<b>2,56</b>	<b>1,32</b>	<b>3,89</b>	<b>1,22</b>	<b>2,54</b>	<b>5,10</b>

Number of theoretical shares in million	434,8	434,8	434,8	434,8	434,8	434,8	434,8	434,8
---	-------	-------	-------	-------	-------	-------	-------	-------

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

\*\*\* for continuing operations

Sum of items may not foot due to rounding.

## Breakdown of depreciation and amortization and adjustments

Group	Division	2018								
		Q1	Q2	H1	Q3	9M	Q4	H2	FY	
€ million										
<b>a) Depreciation and amortization</b>										
<b>Regular depreciation and amortization*</b>	all	<b>132,6</b>	<b>141,5</b>	<b>274,1</b>	<b>136,6</b>	<b>410,7</b>	<b>160,7</b>	<b>297,3</b>	<b>571,4</b>	
<b>Amortization of purchased intangible assets</b>										
Healthcare	HC	139,3	135,1	274,4	135,0	409,4	154,7	289,7	564,1	
Life Science	LS	118,5	121,4	239,9	119,5	359,4	122,2	241,6	481,6	
Performance Materials	PM	31,6	32,4	64,0	32,0	96,0	33,0	65,0	128,9	
<b>Total</b>		<b>289,4</b>	<b>288,9</b>	<b>578,3</b>	<b>286,5</b>	<b>864,8</b>	<b>309,8</b>	<b>596,3</b>	<b>1 174,6</b>	
<b>Impairments**</b>	all	<b>0,0</b>	<b>17,4</b>	<b>17,4</b>	<b>4,5</b>	<b>21,9</b>	<b>33,1</b>	<b>37,6</b>	<b>55,0</b>	
<b>Total depreciation and amortization</b>		<b>422,0</b>	<b>447,8</b>	<b>869,8</b>	<b>427,6</b>	<b>1 297,4</b>	<b>503,6</b>	<b>931,2</b>	<b>1 801,0</b>	
<b>b) Adjustments</b>										
<b>Acquisition costs</b>		<b>0,6</b>	<b>0,3</b>	<b>0,8</b>	<b>0,9</b>	<b>1,7</b>	<b>0,0</b>	<b>1,0</b>	<b>1,8</b>	
<b>Restructuring costs</b>										
Healthcare	HC	-0,7	0,7	-0,1	5,3	5,3	6,3	11,6	11,5	
Life Science	LS	0,2	1,0	1,2	-1,6	-0,4	3,3	1,7	2,9	
Performance Materials	PM	0,0	0,0	0,0	0,0	0,0	1,1	1,1	1,2	
Corporate/Others	CO	6,2	8,8	15,0	5,6	20,6	9,9	15,5	30,5	
<b>Total</b>		<b>5,6</b>	<b>10,5</b>	<b>16,1</b>	<b>9,3</b>	<b>25,4</b>	<b>20,7</b>	<b>30,0</b>	<b>46,1</b>	
<b>Integration costs/IT costs</b>										
Integration Cost	LS/PM/CO	7,6	4,0	11,6	8,9	20,5	48,2	57,1	68,7	
ERP/HR systems	all	13,2	17,5	30,7	13,8	44,5	28,8	42,6	73,3	
<b>Total</b>		<b>20,9</b>	<b>21,5</b>	<b>42,3</b>	<b>22,7</b>	<b>65,0</b>	<b>77,0</b>	<b>99,7</b>	<b>142,0</b>	
<b>Gain (-)/ losses (+) on the divestment of businesses</b>										
Costs related to former business activities	CO	2,1	0,2	2,3	5,5	7,8	-1,1	4,4	6,7	
Costs related to former business activities	PM	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	
Sale of Kuvan and Biosimilars	HC	0,0	36,8	36,7	-1,8	34,9	-9,0	-10,8	25,9	
Costs related to former business activities	LS	-0,2	0,0	-0,2	0,0	-0,2	-7,9	-7,9	-8,0	
<b>Total</b>		<b>1,9</b>	<b>37,0</b>	<b>38,9</b>	<b>3,7</b>	<b>42,6</b>	<b>-18,0</b>	<b>-14,3</b>	<b>24,6</b>	
<b>Other one-time costs</b>										
Others	HC	0,6	-0,9	-0,3	0,6	0,3	7,7	8,3	8,0	
	LS	0,9	-0,2	0,8	0,0	0,7	2,3	2,2	3,0	
	PM	0,8	0,1	0,9	0,0	0,9	-0,2	-0,2	0,7	
	CO	11,7	11,6	23,2	7,4	30,6	15,7	23,1	46,3	
<b>Total</b>		<b>14,0</b>	<b>10,6</b>	<b>24,6</b>	<b>8,0</b>	<b>32,6</b>	<b>25,4</b>	<b>33,4</b>	<b>58,0</b>	
<b>Total adjustments</b>		<b>42,9</b>	<b>79,9</b>	<b>122,8</b>	<b>44,6</b>	<b>167,3</b>	<b>105,2</b>	<b>149,7</b>	<b>272,5</b>	

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impairments

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.



**Income Statement Merck KGaA, Darmstadt, Germany**
**Healthcare**

€ million

	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Net sales</b>	<b>1 434,5</b>	<b>1 584,2</b>	<b>3 018,7</b>	<b>1 596,4</b>	<b>4 615,1</b>	<b>1 630,4</b>	<b>3 226,8</b>	<b>6 245,5</b>
Cost of sales	-333,6	-343,0	-676,6	-363,8	-1 040,4	-384,7	-748,5	-1 425,2
thereof amortization of intangible assets	-0,8	-0,8	-1,6	-0,8	-2,5	-0,8	-1,6	-3,3
Gross profit	1 100,9	1 241,2	2 342,1	1 232,6	3 574,7	1 245,7	2 478,3	4 820,4
<i>in % of net sales</i>	76,7%	78,4%	77,6%	77,2%	77,5%	76,4%	76,8%	77,2%
SG&A	-527,6	-679,2	-1 206,8	-632,1	-1 838,9	-563,0	-1 195,1	-2 401,9
<i>in % of net sales</i>	36,8%	42,9%	40,0%	39,6%	39,8%	34,5%	37,0%	38,5%
Marketing and selling expenses	-550,4	-591,6	-1 142,1	-573,1	-1 715,1	-633,6	-1 206,7	-2 348,7
thereof amortization of intangible assets (M&S)	-138,1	-134,0	-272,1	-133,9	-406,0	-133,8	-267,6	-539,8
Administration expenses	-76,9	-82,1	-159,0	-81,5	-240,5	-88,8	-170,3	-329,4
Impairment losses and reversals (IFRS 9)	-0,5	-4,9	-5,4	-2,9	-8,3	5,3	2,4	-3,0
Other operating expenses/income	100,2	-0,6	99,7	25,4	125,1	154,1	179,5	279,2
Impairments**	0,0	0,0	0,0	0,0	0,0	-11,4	-11,4	-11,4
Research and development	-378,5	-406,6	-785,1	-409,4	-1 194,5	-492,6	-902,0	-1 687,0
<i>in % of net sales</i>	26,4%	25,7%	26,0%	25,6%	25,9%	30,2%	28,0%	27,0%
thereof amortization of intangible assets (R&D)	-0,4	-0,4	-0,7	-0,4	-1,1	-20,1	-20,5	-21,2
<b>EBIT</b>	<b>194,7</b>	<b>155,4</b>	<b>350,2</b>	<b>191,1</b>	<b>541,3</b>	<b>190,1</b>	<b>381,3</b>	<b>731,4</b>
<i>in % of net sales</i>	13,6%	9,8%	11,6%	12,0%	11,7%	11,7%	11,8%	11,7%
Depreciation and amortization	183,9	182,9	366,8	181,1	547,8	213,0	394,1	760,8
<b>EBITDA</b>	<b>378,6</b>	<b>338,3</b>	<b>716,9</b>	<b>372,2</b>	<b>1 089,1</b>	<b>403,1</b>	<b>775,3</b>	<b>1 492,2</b>
<i>in % of net sales</i>	26,4%	21,4%	23,8%	23,3%	23,6%	24,7%	24,0%	23,9%
<b>EBITDA pre</b>	<b>381,4</b>	<b>378,5</b>	<b>759,9</b>	<b>381,5</b>	<b>1 141,4</b>	<b>414,3</b>	<b>795,8</b>	<b>1 555,7</b>
<i>in % of net sales</i>	26,6%	23,9%	25,2%	23,9%	24,7%	25,4%	24,7%	24,9%
<b>Reconciliation to EBITDA pre</b>								
EBITDA	378,6	338,3	716,9	372,2	1 089,1	403,1	775,3	1 492,2
<b>Adjustments</b>								
thereof: Cost of Sales	0,2	-0,3	-0,1	0,0	-0,1	6,6	6,6	6,5
thereof: Marketing and selling expenses	-0,4	0,1	-0,3	1,6	1,3	8,8	10,4	10,1
thereof: Administration expenses	3,0	3,6	6,6	9,1	15,7	12,7	21,7	28,4
thereof: Other operating expenses/income	0,0	36,8	36,8	-1,4	35,3	-17,8	-19,2	17,5
thereof: Research and development	0,0	0,0	-0,1	0,0	-0,1	1,0	1,0	0,9
<b>Total</b>	<b>2,7</b>	<b>40,2</b>	<b>42,9</b>	<b>9,2</b>	<b>52,2</b>	<b>11,2</b>	<b>20,4</b>	<b>63,4</b>
<b>EBITDA pre</b>	<b>381,4</b>	<b>378,5</b>	<b>759,9</b>	<b>381,5</b>	<b>1 141,4</b>	<b>414,3</b>	<b>795,8</b>	<b>1 555,7</b>

Sum of items may not foot due to rounding.

## Detailed reconciliation - Healthcare

€ million	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>194,7</b>	<b>155,4</b>	<b>350,2</b>	<b>191,1</b>	<b>541,3</b>	<b>190,1</b>	<b>381,3</b>	<b>731,4</b>
Regular depreciation and amortization*	44,6	47,7	92,4	46,1	138,4	46,9	93,0	185,3
Amortization of purchased intangible assets	139,3	135,1	274,4	135,0	409,4	154,7	289,7	564,1
Impairments**	0,0	0,0	0,0	0,0	0,0	11,4	11,4	11,4
<b>Total depreciation and amortization</b>	<b>183,9</b>	<b>182,9</b>	<b>366,8</b>	<b>181,1</b>	<b>547,8</b>	<b>213,0</b>	<b>394,1</b>	<b>760,8</b>
<b>EBITDA</b>	<b>378,6</b>	<b>338,3</b>	<b>716,9</b>	<b>372,2</b>	<b>1 089,1</b>	<b>403,1</b>	<b>775,3</b>	<b>1 492,2</b>
<b>Adjustments</b>								
<b>Acquisition costs</b>	<b>0,1</b>	<b>-0,1</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>
<b>Restructuring costs</b>								
Restructuring costs	-0,7	0,7	-0,1	5,3	5,3	6,3	11,6	11,5
<b>Total</b>	<b>-0,7</b>	<b>0,7</b>	<b>-0,1</b>	<b>5,3</b>	<b>5,3</b>	<b>6,3</b>	<b>11,6</b>	<b>11,5</b>
<b>Integration costs/IT costs</b>								
Integration Cost	0,0	0,0	0,0	0,0	0,0	0,7	0,7	0,8
ERP/HR systems	2,8	3,7	6,5	5,1	11,7	5,5	10,6	17,1
<b>Total</b>	<b>2,8</b>	<b>3,7</b>	<b>6,5</b>	<b>5,1</b>	<b>11,7</b>	<b>6,2</b>	<b>11,4</b>	<b>17,9</b>
<b>Gain (-)/ losses (+) on the divestment of businesses</b>								
Sale of Kuvan and Biosimilars	0,0	36,8	36,7	-1,8	34,9	-9,0	-10,8	25,9
<b>Total</b>	<b>0,0</b>	<b>36,8</b>	<b>36,7</b>	<b>-1,8</b>	<b>34,9</b>	<b>-9,0</b>	<b>-10,8</b>	<b>25,9</b>
<b>Other one-time costs</b>								
Others	0,6	-0,9	-0,3	0,6	0,3	7,7	8,3	8,0
<b>Total</b>	<b>0,6</b>	<b>-0,9</b>	<b>-0,3</b>	<b>0,6</b>	<b>0,3</b>	<b>7,7</b>	<b>8,3</b>	<b>8,0</b>
<b>Total adjustments</b>	<b>2,7</b>	<b>40,2</b>	<b>42,9</b>	<b>9,2</b>	<b>52,2</b>	<b>11,2</b>	<b>20,4</b>	<b>63,4</b>
<b>EBITDA pre</b>	<b>381,4</b>	<b>378,5</b>	<b>759,9</b>	<b>381,5</b>	<b>1 141,4</b>	<b>414,3</b>	<b>795,8</b>	<b>1 555,7</b>

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impai

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**
**Life Science**

€ million

	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Net sales</b>	<b>1 487,2</b>	<b>1 542,8</b>	<b>3 030,1</b>	<b>1 527,4</b>	<b>4 557,5</b>	<b>1 627,7</b>	<b>3 155,1</b>	<b>6 185,2</b>
Cost of sales	-650,1	-677,4	-1 327,5	-656,2	-1 983,8	-738,9	-1 395,1	-2 722,6
thereof amortization of intangible assets	-14,4	-14,6	-29,0	-14,7	-43,7	-14,9	-29,6	-58,6
Gross profit	837,1	865,4	1 702,5	871,2	2 573,7	888,9	1 760,1	3 462,6
<i>in % of net sales</i>	56,3%	56,1%	56,2%	57,0%	56,5%	54,6%	55,8%	56,0%
SG&A	-504,6	-550,5	-1 055,1	-535,4	-1 590,4	-585,6	-1 121,0	-2 176,1
<i>in % of net sales</i>	33,9%	35,7%	34,8%	35,0%	34,9%	36,0%	35,5%	35,2%
Marketing and selling expenses	-409,1	-452,2	-861,3	-442,8	-1 304,1	-472,8	-915,6	-1 776,9
thereof amortization of intangible assets (M&S)	-104,1	-106,7	-210,8	-104,7	-315,6	-107,3	-212,0	-422,8
Administration expenses	-77,8	-65,5	-143,3	-84,9	-228,2	-106,4	-191,3	-334,6
Impairment losses and reversals (IFRS 9)	-1,4	-0,4	-1,8	0,1	-1,7	-2,6	-2,5	-4,3
Other operating expenses/income	-16,4	-32,3	-48,7	-7,8	-56,5	-3,8	-11,6	-60,3
Impairments**	0,0	-16,3	-16,3	-4,6	-20,8	-2,1	-6,6	-22,9
Research and development	-59,5	-60,9	-120,4	-59,1	-179,5	-71,4	-130,6	-251,0
<i>in % of net sales</i>	4,0%	3,9%	4,0%	3,9%	3,9%	4,4%	4,1%	4,1%
thereof amortization of intangible assets (R&D)	-0,1	0,0	-0,1	0,0	-0,1	0,0	0,0	-0,1
<b>EBIT</b>	<b>273,0</b>	<b>254,0</b>	<b>527,0</b>	<b>276,7</b>	<b>803,8</b>	<b>231,8</b>	<b>508,5</b>	<b>1 035,6</b>
<i>in % of net sales</i>	18,4%	16,5%	17,4%	18,1%	17,6%	14,2%	16,1%	16,7%
Depreciation and amortization	168,6	188,4	357,1	172,6	529,6	189,8	362,3	719,4
<b>EBITDA</b>	<b>441,6</b>	<b>442,5</b>	<b>884,1</b>	<b>449,3</b>	<b>1 333,4</b>	<b>421,6</b>	<b>870,9</b>	<b>1 755,0</b>
<i>in % of net sales</i>	29,7%	28,7%	29,2%	29,4%	29,3%	25,9%	27,6%	28,4%
<b>EBITDA pre</b>	<b>454,6</b>	<b>451,8</b>	<b>906,4</b>	<b>460,3</b>	<b>1 366,7</b>	<b>473,6</b>	<b>933,9</b>	<b>1 840,3</b>
<i>in % of net sales</i>	30,6%	29,3%	29,9%	30,1%	30,0%	29,1%	29,6%	29,8%
<b>Reconciliation to EBITDA pre</b>								
EBITDA	441,6	442,5	884,1	449,3	1 333,4	421,6	870,9	1 755,0
<b>Adjustments</b>								
thereof: Cost of Sales	2,8	3,4	6,2	-4,6	1,6	35,9	31,3	37,6
thereof: Marketing and selling expenses	0,8	1,6	2,4	-0,2	2,1	0,2	0,0	2,3
thereof: Administration expenses	8,3	5,4	13,7	15,6	29,3	23,1	38,7	52,4
thereof: Other operating expenses/income	1,0	-1,2	-0,2	0,2	-0,1	-8,4	-8,2	-8,5
thereof: Research and development	0,1	0,1	0,2	0,2	0,3	1,1	1,3	1,5
<b>Total</b>	<b>13,0</b>	<b>9,3</b>	<b>22,3</b>	<b>11,0</b>	<b>33,3</b>	<b>52,0</b>	<b>63,1</b>	<b>85,3</b>
<b>EBITDA pre</b>	<b>454,6</b>	<b>451,8</b>	<b>906,4</b>	<b>460,3</b>	<b>1 366,7</b>	<b>473,6</b>	<b>933,9</b>	<b>1 840,3</b>

Sum of items may not foot due to rounding.

## Detailed reconciliation - Life Science

€ million	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>273,0</b>	<b>254,0</b>	<b>527,0</b>	<b>276,7</b>	<b>803,8</b>	<b>231,8</b>	<b>508,5</b>	<b>1 035,6</b>
Regular depreciation and amortization*	50,1	50,8	100,9	48,5	149,4	65,5	114,1	214,9
Amortization of purchased intangible assets	118,5	121,4	239,9	119,5	359,4	122,2	241,6	481,6
Impairments**	0,0	16,3	16,3	4,6	20,8	2,1	6,6	22,9
<b>Total depreciation and amortization</b>	<b>168,6</b>	<b>188,4</b>	<b>357,1</b>	<b>172,6</b>	<b>529,6</b>	<b>189,8</b>	<b>362,3</b>	<b>719,4</b>
<b>EBITDA</b>	<b>441,6</b>	<b>442,5</b>	<b>884,1</b>	<b>449,3</b>	<b>1 333,4</b>	<b>421,6</b>	<b>870,9</b>	<b>1 755,0</b>
<b>Adjustments</b>								
<b>Acquisition costs</b>	<b>0,5</b>	<b>0,3</b>	<b>0,8</b>	<b>0,9</b>	<b>1,7</b>	<b>0,0</b>	<b>1,0</b>	<b>1,8</b>
<b>Restructuring costs</b>								
Restructuring costs	0,2	1,0	1,2	-1,6	-0,4	3,3	1,7	2,9
<b>Total</b>	<b>0,2</b>	<b>1,0</b>	<b>1,2</b>	<b>-1,6</b>	<b>-0,4</b>	<b>3,3</b>	<b>1,7</b>	<b>2,9</b>
<b>Integration costs/IT costs</b>								
Integration Cost	7,3	4,0	11,3	8,7	20,0	46,7	55,3	66,6
ERP/HR systems	4,3	4,1	8,3	3,1	11,4	7,6	10,7	19,0
<b>Total</b>	<b>11,6</b>	<b>8,1</b>	<b>19,7</b>	<b>11,8</b>	<b>31,4</b>	<b>54,3</b>	<b>66,0</b>	<b>85,7</b>
<b>Gain (-)/ losses (+) on the divestment of businesses</b>								
Costs related to former business activities	-0,2	0,0	-0,2	0,0	-0,2	-7,9	-7,9	-8,0
<b>Total</b>	<b>-0,2</b>	<b>0,0</b>	<b>-0,2</b>	<b>0,0</b>	<b>-0,2</b>	<b>-7,9</b>	<b>-7,9</b>	<b>-8,0</b>
<b>Other one-time costs</b>								
Others	0,9	-0,2	0,8	0,0	0,7	2,3	2,2	3,0
<b>Total</b>	<b>0,9</b>	<b>-0,2</b>	<b>0,8</b>	<b>0,0</b>	<b>0,7</b>	<b>2,3</b>	<b>2,2</b>	<b>3,0</b>
<b>Total adjustments</b>	<b>13,0</b>	<b>9,3</b>	<b>22,3</b>	<b>11,0</b>	<b>33,3</b>	<b>52,0</b>	<b>63,1</b>	<b>85,3</b>
<b>EBITDA pre</b>	<b>454,6</b>	<b>451,8</b>	<b>906,4</b>	<b>460,3</b>	<b>1 366,7</b>	<b>473,6</b>	<b>933,9</b>	<b>1 840,3</b>

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impai

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**
**Performance Materials**

€ million

	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Net sales</b>	<b>564,0</b>	<b>586,5</b>	<b>1 150,5</b>	<b>625,6</b>	<b>1 776,1</b>	<b>629,5</b>	<b>1 255,0</b>	<b>2 405,6</b>
Cost of sales	-275,4	-299,8	-575,3	-321,9	-897,2	-333,7	-655,6	-1 230,9
thereof amortization of intangible assets	-27,9	-28,5	-56,4	-28,3	-84,7	-28,8	-57,2	-113,6
Gross profit	288,5	286,7	575,2	303,7	878,9	295,8	599,5	1 174,7
<i>in % of net sales</i>	51,2%	48,9%	50,0%	48,5%	49,5%	47,0%	47,8%	48,8%
SG&A	-93,9	-96,5	-190,4	-96,7	-287,0	-138,3	-235,0	-425,3
<i>in % of net sales</i>	16,6%	16,4%	16,5%	15,5%	16,2%	22,0%	18,7%	17,7%
Marketing and selling expenses	-59,8	-60,8	-120,6	-62,1	-182,7	-71,8	-133,9	-254,5
thereof amortization of intangible assets (M&S)	-2,9	-3,1	-6,0	-2,9	-8,9	-3,2	-6,0	-12,1
Administration expenses	-21,9	-27,3	-49,2	-23,3	-72,5	-34,2	-57,5	-106,6
Impairment losses and reversals (IFRS 9)	-0,5	0,2	-0,3	-0,2	-0,4	-0,2	-0,4	-0,7
Other operating expenses/income	-11,7	-8,5	-20,3	-11,1	-31,4	-32,2	-43,3	-63,5
Impairments**	0,0	-1,1	-1,1	0,0	-1,1	-19,6	-19,6	-20,7
Research and development	-59,0	-59,1	-118,1	-64,7	-182,8	-59,0	-123,7	-241,8
<i>in % of net sales</i>	10,5%	10,1%	10,3%	10,3%	10,3%	9,4%	9,9%	10,1%
thereof amortization of intangible assets (R&D)	-0,7	-0,9	-1,6	-0,8	-2,4	-1,0	-1,8	-3,3
<b>EBIT</b>	<b>135,7</b>	<b>131,1</b>	<b>266,8</b>	<b>142,3</b>	<b>409,1</b>	<b>98,4</b>	<b>240,8</b>	<b>507,5</b>
<i>in % of net sales</i>	24,1%	22,4%	23,2%	22,8%	23,0%	15,6%	19,2%	21,1%
Depreciation and amortization	56,8	60,5	117,3	59,7	177,0	84,3	143,9	261,2
<b>EBITDA</b>	<b>192,5</b>	<b>191,6</b>	<b>384,1</b>	<b>202,0</b>	<b>586,1</b>	<b>182,7</b>	<b>384,7</b>	<b>768,8</b>
<i>in % of net sales</i>	34,1%	32,7%	33,4%	32,3%	33,0%	29,0%	30,7%	32,0%
<b>EBITDA pre</b>	<b>195,7</b>	<b>195,8</b>	<b>391,5</b>	<b>203,2</b>	<b>594,7</b>	<b>190,9</b>	<b>394,0</b>	<b>785,5</b>
<i>in % of net sales</i>	34,7%	33,4%	34,0%	32,5%	33,5%	30,3%	31,4%	32,7%
<b>Reconciliation to EBITDA pre</b>								
EBITDA	192,5	191,6	384,1	202,0	586,1	182,7	384,7	768,8
<b>Adjustments</b>								
thereof: Cost of Sales	0,0	0,2	0,2	-0,2	0,0	0,4	0,2	0,4
thereof: Marketing and selling expenses	0,0	0,0	0,0	0,1	0,1	-0,2	-0,1	-0,1
thereof: Administration expenses	3,2	4,0	7,2	1,4	8,5	8,0	9,3	16,5
thereof: Other operating expenses/income	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
thereof: Research and development	0,0	0,0	0,0	-0,1	-0,1	0,0	-0,1	-0,1
<b>Total</b>	<b>3,2</b>	<b>4,2</b>	<b>7,4</b>	<b>1,1</b>	<b>8,6</b>	<b>8,2</b>	<b>9,3</b>	<b>16,8</b>
<b>EBITDA pre</b>	<b>195,7</b>	<b>195,8</b>	<b>391,5</b>	<b>203,2</b>	<b>594,7</b>	<b>190,9</b>	<b>394,0</b>	<b>785,5</b>

Sum of items may not foot due to rounding.

## Detailed reconciliation - Performance Materials

€ million	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>135,7</b>	<b>131,1</b>	<b>266,8</b>	<b>142,3</b>	<b>409,1</b>	<b>98,4</b>	<b>240,8</b>	<b>507,5</b>
Regular depreciation and amortization*	25,3	26,9	52,2	27,7	79,9	31,7	59,4	111,6
Amortization of purchased intangible assets	31,6	32,4	64,0	32,0	96,0	33,0	65,0	128,9
Impairments**	0,0	1,1	1,1	0,0	1,1	19,6	19,6	20,7
<b>Total depreciation and amortization</b>	<b>56,8</b>	<b>60,5</b>	<b>117,3</b>	<b>59,7</b>	<b>177,0</b>	<b>84,3</b>	<b>143,9</b>	<b>261,2</b>
<b>EBITDA</b>	<b>192,5</b>	<b>191,6</b>	<b>384,1</b>	<b>202,0</b>	<b>586,1</b>	<b>182,7</b>	<b>384,7</b>	<b>768,8</b>
<b>Adjustments</b>								
<b>Acquisition costs</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>
<b>Restructuring costs</b>								
Restructuring costs	0,0	0,0	0,0	0,0	0,0	1,1	1,1	1,2
<b>Total</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>1,1</b>	<b>1,1</b>	<b>1,2</b>
<b>Integration costs/IT costs</b>								
Integration Cost	0,1	-0,1	0,1	0,0	0,1	0,4	0,4	0,5
ERP/HR systems	2,3	4,2	6,5	1,1	7,6	6,8	8,0	14,4
<b>Total</b>	<b>2,4</b>	<b>4,1</b>	<b>6,5</b>	<b>1,1</b>	<b>7,7</b>	<b>7,3</b>	<b>8,4</b>	<b>14,9</b>
<b>Gain (-)/ losses (+) on the divestment of businesses</b>								
Costs related to former business activities	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
<b>Total</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>
<b>Other one-time costs</b>								
Others	0,8	0,1	0,9	0,0	0,9	-0,2	-0,2	0,7
<b>Total</b>	<b>0,8</b>	<b>0,1</b>	<b>0,9</b>	<b>0,0</b>	<b>0,9</b>	<b>-0,2</b>	<b>-0,2</b>	<b>0,7</b>
<b>Total adjustments</b>	<b>3,2</b>	<b>4,2</b>	<b>7,4</b>	<b>1,1</b>	<b>8,6</b>	<b>8,2</b>	<b>9,3</b>	<b>16,8</b>
<b>EBITDA pre</b>	<b>195,7</b>	<b>195,8</b>	<b>391,5</b>	<b>203,2</b>	<b>594,7</b>	<b>190,9</b>	<b>394,0</b>	<b>785,5</b>

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impai

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.

**Income Statement Merck KGaA, Darmstadt, Germany**
**Corporate/Others**

€ million

	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>Net sales</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>
Cost of sales	-0,8	-1,1	-1,9	-2,2	-4,1	1,0	-1,3	-3,2
thereof amortization of intangible assets	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Gross profit	-0,8	-1,1	-1,9	-2,2	-4,1	1,0	-1,3	-3,2
SG&A	-89,8	-135,3	-225,1	-107,9	-333,0	-164,4	-272,3	-497,4
Marketing and selling expenses	-1,4	-4,1	-5,5	-0,8	-6,3	-10,0	-10,9	-16,3
thereof amortization of intangible assets (M&S)	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Administration expenses	-80,8	-99,9	-180,7	-93,4	-274,1	-138,7	-232,1	-412,8
Impairment losses and reversals (IFRS 9)	0,0	-0,6	-0,6	35,3	34,6	0,7	36,0	35,3
Other operating expenses/income	-7,6	-30,7	-38,3	-49,0	-87,3	-16,3	-65,3	-103,6
Impairments**	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Research and development	-10,6	-11,8	-22,4	-9,0	-31,5	-16,0	-25,0	-47,4
thereof amortization of intangible assets (R&D)	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
<b>EBIT</b>	<b>-101,2</b>	<b>-148,2</b>	<b>-249,4</b>	<b>-119,2</b>	<b>-368,6</b>	<b>-179,4</b>	<b>-298,6</b>	<b>-548,0</b>
Depreciation and amortization	12,7	16,0	28,7	14,3	43,0	16,5	30,8	59,5
<b>EBITDA</b>	<b>-88,5</b>	<b>-132,2</b>	<b>-220,8</b>	<b>-104,9</b>	<b>-325,6</b>	<b>-162,9</b>	<b>-267,7</b>	<b>-488,5</b>
<b>EBITDA pre</b>	<b>-64,6</b>	<b>-106,0</b>	<b>-170,6</b>	<b>-81,7</b>	<b>-252,4</b>	<b>-129,1</b>	<b>-210,8</b>	<b>-381,5</b>

**Reconciliation to EBITDA pre**

EBITDA	-88,5	-132,2	-220,8	-104,9	-325,6	-162,9	-267,7	-488,5
<b>Adjustments</b>								
thereof: Cost of Sales	0,0	0,0	0,0	0,2	0,2	0,0	0,2	0,2
thereof: Marketing and selling expenses	0,0	0,2	0,2	-0,1	0,2	0,4	0,3	0,6
thereof: Administration expenses	21,8	25,7	47,6	17,5	65,1	27,6	45,1	92,7
thereof: Other operating expenses/income	2,1	0,3	2,4	5,5	7,8	5,7	11,1	13,5
thereof: Research and development	0,0	0,0	0,0	0,0	0,0	0,1	0,1	0,1
<b>Total</b>	<b>24,0</b>	<b>26,2</b>	<b>50,1</b>	<b>23,1</b>	<b>73,3</b>	<b>33,8</b>	<b>56,9</b>	<b>107,0</b>
<b>EBITDA pre</b>	<b>-64,6</b>	<b>-106,0</b>	<b>-170,6</b>	<b>-81,7</b>	<b>-252,4</b>	<b>-129,1</b>	<b>-210,8</b>	<b>-381,5</b>

Sum of items may not foot due to rounding.

## Detailed reconciliation - Corporate / Others

€ million	2018							
	Q1	Q2	H1	Q3	9M	Q4	H2	FY
<b>EBIT</b>	<b>-101,2</b>	<b>-148,2</b>	<b>-249,4</b>	<b>-119,2</b>	<b>-368,6</b>	<b>-179,4</b>	<b>-298,6</b>	<b>-548,0</b>
Regular depreciation and amortization*	12,6	16,0	28,7	14,3	43,0	16,5	30,8	59,5
Amortization of purchased intangible assets	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
Impairments**	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0
<b>Total depreciation and amortization</b>	<b>12,7</b>	<b>16,0</b>	<b>28,7</b>	<b>14,3</b>	<b>43,0</b>	<b>16,5</b>	<b>30,8</b>	<b>59,5</b>
<b>EBITDA</b>	<b>-88,5</b>	<b>-132,2</b>	<b>-220,8</b>	<b>-104,9</b>	<b>-325,6</b>	<b>-162,9</b>	<b>-267,7</b>	<b>-488,5</b>
<b>Adjustments</b>								
<b>Acquisition costs</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>	<b>0,0</b>
<b>Restructuring costs</b>								
Restructuring costs	6,2	8,8	15,0	5,6	20,6	9,9	15,5	30,5
<b>Total</b>	<b>6,2</b>	<b>8,8</b>	<b>15,0</b>	<b>5,6</b>	<b>20,6</b>	<b>9,9</b>	<b>15,5</b>	<b>30,5</b>
<b>IT project costs</b>								
Integration Cost	0,2	0,0	0,2	0,2	0,4	0,3	0,6	0,8
ERP/HR systems	3,9	5,5	9,4	4,4	13,8	8,9	13,3	22,7
<b>Total</b>	<b>4,1</b>	<b>5,5</b>	<b>9,6</b>	<b>4,6</b>	<b>14,2</b>	<b>9,3</b>	<b>13,9</b>	<b>23,5</b>
<b>Gain (-)/ losses (+) on the divestment of businesses</b>								
Costs related to former business activities	2,1	0,2	2,3	5,5	7,8	-1,1	4,4	6,7
<b>Total</b>	<b>2,1</b>	<b>0,2</b>	<b>2,3</b>	<b>5,5</b>	<b>7,8</b>	<b>-1,1</b>	<b>4,4</b>	<b>6,7</b>
<b>Other one-time costs</b>								
Others	11,7	11,6	23,2	7,4	30,6	15,7	23,1	46,3
<b>Total</b>	<b>11,7</b>	<b>11,6</b>	<b>23,2</b>	<b>7,4</b>	<b>30,6</b>	<b>15,7</b>	<b>23,1</b>	<b>46,3</b>
<b>Total adjustments</b>	<b>24,0</b>	<b>26,2</b>	<b>50,1</b>	<b>23,1</b>	<b>73,3</b>	<b>33,8</b>	<b>56,9</b>	<b>107,0</b>
<b>EBITDA pre</b>	<b>-64,6</b>	<b>-106,0</b>	<b>-170,6</b>	<b>-81,7</b>	<b>-252,4</b>	<b>-129,1</b>	<b>-210,8</b>	<b>-381,5</b>

\* Regular depreciation and amortization = Depreciation and amortization - Amortization of purchased intangible assets - Impai

\*\* only reflects impairments which classified as adjustments

Sum of items may not foot due to rounding.